Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on My Health News Nevada.
Press releases published on May 14, 2025
Health 2.0 Conference’s USA 2026 Edition To Review Billing Fraud In Healthcare
EIN Presswire
·
May 14, 2025
The 2026 healthcare event will address billing fraud in healthcare and bring experts together to discuss prevention, detection, and ethical practices. LAS VEGAS, NV, UNITED STATES, May 14, 2025 /EINPresswire.com/ -- The Health 2.0 Conference, set to be …
Natural Alternatives International, Inc. Announces 2025 Q3 and YTD Results
GlobeNewswire
·
May 14, 2025
CARLSBAD, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Natural Alternatives International, Inc. ("NAI") (Nasdaq: NAII), a leading formulator, manufacturer, and marketer of customized nutritional supplements, today announced a net loss of $2.2 million, or $0.37 …
Precipio Announces its Q1-2025 Financial Results
GlobeNewswire
·
May 14, 2025
NEW HAVEN, Conn., May 14, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), filed its 10-Q report today. The following are the highlights of the Company’s financial performance and outlook for 2025. “We remain …
SS Innovations Reports First Quarter 2025 Financial Results
GlobeNewswire
·
May 14, 2025
Record Quarterly Revenue of $5.1 Million Driven by Higher SSi Mantra 3 Unit Sales On Track for July 2025 De Novo Application to the FDA for SSi Mantra 3 FORT LAUDERDALE, Fla., May 14, 2025 (GLOBE NEWSWIRE) -- SS Innovations International, Inc. (the “ …
Calidi Biotherapeutics Reports First Quarter 2025 Financial Results and Recent Operational Highlights
GlobeNewswire
·
May 14, 2025
Bolstered management team with hires of Chief Executive Officer and Chief Medical Officer with deep biopharmaceutical experience Announced selection of IL15-superagonist as first payload to be delivered into tumors with Calidi’s first lead candidate using …
STERIS Announces Financial Results for Fiscal 2025 Fourth Quarter and Full Year
GlobeNewswire
·
May 14, 2025
Full year fiscal 2025 revenue from continuing operations increased 6%; constant currency organic revenue growth was 6% Full year fiscal 2025 as reported diluted EPS from continuing operations increased to $6.16; adjusted EPS per diluted share increased to …
FibroBiologics Reports First Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewswire
·
May 14, 2025
HOUSTON, May 14, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 240+ patents issued and pending for the development of therapeutics and potential cures for chronic diseases using …
Catheter Precision, Inc. Announces First Quarter 2025 Update and Financial Results
GlobeNewswire
·
May 14, 2025
FORT MILL, S.C., May 14, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE American: VTAK), a U.S.-based innovative medical device company focused on electrophysiology products, today announced its financial results and operational update for the …
ImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2025
GlobeNewswire
·
May 14, 2025
PORTLAND, Maine, May 14, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the …
Zentalis Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Progress
GlobeNewswire
·
May 14, 2025
First patient dosed in DENALI Part 2a clinical trial of azenosertib in patients with Cyclin E1+ PROC Topline data from DENALI Part 2 anticipated by year end 2026 with the potential to support an accelerated approval, subject to FDA feedback $332.5 million …
Jade Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewswire
·
May 14, 2025
Completed reverse merger and commenced trading on Nasdaq as JBIO Closed financing, raising approximately $300 million to date, providing cash runway through 2027 Lead candidate JADE101 expected to enter the clinic in second half of 2025, with interim …
Tenax Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewswire
·
May 14, 2025
Phase 3 LEVEL Enrollment Completion for TNX-103 in PH-HFpEF Targeted Around Year-End 2025, with Topline Data Expected Middle of 2026 Initiation of Second Phase 3 Study, LEVEL-2, Expected This Year CHAPEL HILL, N.C., May 14, 2025 (GLOBE NEWSWIRE) -- Tenax …
Sight Sciences to Present at the Stifel 2025 Virtual Ophthalmology Forum on May 27th
GlobeNewswire
·
May 14, 2025
MENLO PARK, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform …
Vaxart Publishes Positive, Complete Data from a Phase 2b Challenge Study of its First-Generation Oral Pill Norovirus Vaccine Candidate in Science Translational Medicine
GlobeNewswire
·
May 14, 2025
Challenge Study measured safety, efficacy against infection and symptomatic disease as well as viral shedding Machine learning analyses identified statistically significant correlates of protection and will be incorporated into the development of Vaxart’s …
Alumis Reports First Quarter 2025 Financial Results and Highlights Recent Achievements
GlobeNewswire
·
May 14, 2025
SOUTH SAN FRANCISCO, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of …
BioRestorative Therapies Reports First Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
May 14, 2025
MELVILLE, N.Y., May 14, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a regenerative medicine innovator focused on stem cell-based therapies and products, today reported financial results …
Biomea Fusion’s BMF-500 Selected for Poster Presentation at EHA 2025 Highlighting Phase I Data in Relapsed/Refractory Acute Leukemia
GlobeNewswire
·
May 14, 2025
REDWOOD CITY, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today announced that preliminary clinical data from the Phase I COVALENT-103 trial of BMF-500 in …
Journey Medical Corporation Reports First Quarter 2025 Financial Results and Recent Corporate Highlights
GlobeNewswire
·
May 14, 2025
Revenue for the First Quarter Ended March 31, 2025 was $13.1 million Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules) Commercial Launch Off to a Strong Start, Initial Prescriptions Filled in Late March 2025 Phase 3 Clinical Trial Results …
Galapagos kondigt mondelinge presentaties aan tijdens EHA en ICML 2025 met veelbelovende nieuwe resultaten uit de ATALANTA-1 studie met CAR-T kandidaat GLPG5101
GlobeNewswire
·
May 14, 2025
Mechelen, België; 14 mei 2025, 22:01 CET; Galapagos NV (Euronext …
Galapagos Announces Oral Presentations at EHA and ICML 2025 Featuring Promising New Data from ATALANTA-1 study of Investigational CAR-T Candidate GLPG5101
GlobeNewswire
·
May 14, 2025
Mechelen, Belgium; May 14, 2025, 22:01 CET; Galapagos NV (Euronext …